Lupin settles Mirabegron patent dispute with Astellas, agrees to $90 million payout

SUMMARY

AI Generated Content
  • Lupin settles patent row for bladder drug
  • Pays $90m to Astellas for Mirabegron licence
  • Removes US market overhang, boosts revenue visibility
AD
AD